Abingworth, an international investment group dedicated to life sciences and healthcare, held the final closing of its £225m (approximately $375m) fund.
Abingworth Bioventures VI (ABV VI), Abingworth’s 10th life sciences fund, exceeded its target of £200m with the majority of the funds coming from existing investors.
It will focus on investing in life sciences and healthcare both in Europe and the US, broadly across all stages of development including early and late-stage private deals, VIPEs (Venture Investments in Public Equities), venture growth and public equities. The fund i expected to make 15-20 investments with size ranging from £5m to £20m per operation in total after all rounds of financing.
ABV VI has already closed on four deals:
– Avedro (US), technology for corneal crosslinking
– Avillion (UK), structured finance for late-stage drug development
– eFFECTOR (US), novel targets for therapeutics with main focus on cancer
– GenSight Biologics (France), gene therapy for ophthalmology
Led by Stephen Bunting, Managing Partner, Abingworth has offices in London, Menlo Park (California) and Boston.
FinSMEs
28/02/2014
LLP, a Limited Liability Partnership, registered in England No OC320188, registered office as above.
Authorised and regulated by the Financial Services Authority.
Existing Funds
To date, Abingworth has raised 15 funds including 10 venture funds dedicated to investment in
life sciences and healthcare. For a full list of Abingworth’s portfolio companies please visit the
website: www.abingworth.com
This document does not constitute an offer or invitation to subscribe or purchase limited partnership
interests. Any investment in Abingworth Bioventures VI LP will be made solely on the basis of the private
placement memorandum issued in connection therewith and the limited partnership agreement and
associated documentation.
Contact
Dr Stephen Bunting
Managing Partner
Victoria Stewart
Principal, Public Relations
Abingworth
Tel: +44 (0)20 7534 1500
Email: [email protected]
www.abingworth.com